Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gain Therapeutics (GANX) has shared an update.
Gene Mack has been appointed as the new Chief Financial Officer of Gain Therapeutics, Inc., effective April 8, 2024. Bringing a wealth of experience from leading financial roles in several biotech companies, Mack’s responsibilities will include overseeing the company’s financial operations and serving as Secretary. His compensation package includes a $370,000 base salary, potential cash bonuses, and an option to purchase company stock, with provisions for severance under certain conditions. Mack’s appointment is expected to bring seasoned leadership to Gain Therapeutics’ financial strategy as it continues to innovate in the biotechnology sector.
See more insights into GANX stock on TipRanks’ Stock Analysis page.